Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network

Mantle cell lymphoma (MCL) is challenging to manage, with a median survival of 3–5 years. While intensive strategies are often appropriate for younger patients, these approaches are often not appropriate for older patients. In 2006, we reported our initial results using modified R-hyperCVAD (rituxim...

Full description

Saved in:
Bibliographic Details
Main Authors: KENKRE, VAISHALEE P., LONG, WALTER L., EICKHOFF, JENS C., BLANK, JULES H., McFARLAND, THOMAS A., BOTTNER, WAYNE, REZAZEDEH, HAMIED, WERNDLI, JAE E., BAILEY, HOWARD H., KAHL, BRAD S.
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3489168/
https://ncbi.nlm.nih.gov/pubmed/21864042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2011.580404
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items